R-Flurbiprofen Reduces Neuropathic Pain in Rodents by Restoring Endogenous Cannabinoids

@article{Bishay2010RFlurbiprofenRN,
  title={R-Flurbiprofen Reduces Neuropathic Pain in Rodents by Restoring Endogenous Cannabinoids},
  author={Philipp Bishay and Helmut Schmidt and Claudiu Marian and Annett H{\"a}ussler and Nina Wijnvoord and Simone Ziebell and Julia Metzner and Marco Koch and Thekla Myrczek and Ingo Bechmann and Rohini Kuner and Michael Costigan and Faramarz Dehghani and Gerd Geisslinger and Irmgard Tegeder},
  journal={PLoS ONE},
  year={2010},
  volume={5}
}
Background R-flurbiprofen, one of the enantiomers of flurbiprofen racemate, is inactive with respect to cyclooxygenase inhibition, but shows analgesic properties without relevant toxicity. Its mode of action is still unclear. Methodology/Principal Findings We show that R-flurbiprofen reduces glutamate release in the dorsal horn of the spinal cord evoked by sciatic nerve injury and thereby alleviates pain in sciatic nerve injury models of neuropathic pain in rats and mice. This is mediated by… 

Figures from this paper

Analgesic effects of FAAH inhibitor in the insular cortex of nerve-injured rats

The results suggest that microinjection of FAAH inhibitor into the insular cortex causes analgesic effects by decreasing neural excitability and increasing signals related to the endogenous cannabinoid pathway in theinsular cortex.

Alterations in the Anandamide Metabolism in the Development of Neuropathic Pain

The data have shown an alteration of alternative AEA synthesis and degradation pathways, which might contribute to the variation of AEA levels and neuropathic pain development.

Effects of R‐flurbiprofen and the oxygenated metabolites of endocannabinoids in inflammatory pain mice models

The effects of flurbiprofen enantiomers on mechanical hyperalgesia seem to depend on (i) the inflammatory stimuli, (ii) the route of administration, and (iii) the timing of Administration, which support the interest of studying the nonhydrolytic endocannabinoid metabolism in the context of inflammatory pain.

Blockade of P2X4 Receptors Inhibits Neuropathic Pain-Related Behavior by Preventing MMP-9 Activation and, Consequently, Pronociceptive Interleukin Release in a Rat Model

The data provide new evidence that P2X4R may indeed play a significant role in neuropathic pain development by modulating neuroimmune interactions in the spinal cord and DRG, suggesting that its blockade may have potential therapeutic utility.

R-flurbiprofen attenuates experimental autoimmune encephalomyelitis in mice

R‐flurbiprofen reduced immune cell infiltration and microglia activation and inflammation in the spinal cord, brain and optic nerve and attenuated myelin destruction and EAE‐evoked hyperalgesia, and its low toxicity may justify a clinical trial.

Substrate-selective COX-2 inhibition decreases anxiety via endocannabinoid activation

Using medicinal chemistry and in vivo analytical and behavioral pharmacological approaches, it is found that COX-2 is important for the regulation of eCB levels in vivo and substrate-selective pharmacology represents a viable approach for eCB augmentation with broad therapeutic potential.

R-Flurbiprofen Traps Prostaglandins within Cells by Inhibition of Multidrug Resistance-Associated Protein-4

The data show a novel mechanism by which R-flurbiprofen reduces extracellular PGs at physiological concentrations, particularly in cancers with high levels of MRP4, but the mechanism may also contribute to its anti-inflammatory and immune-modulating properties and suggests that it reduces PGs in a site- and context-dependent manner.

Exogenous Delta9-Tetrahydrocannabinol Influences Circulating Endogenous Cannabinoids in Humans

It is shown that administration of a single oral dose of 20 mg THC to 30 healthy volunteers resulted in higher circulating concentrations of anandamide, 2-AG, palmitoyl ethanolamide, and oleoylethanolamide at 2 and 3 hours after administration as compared with placebo, suggesting that exogenous cannabinoids may lead to changes in the endocannabinoid system that can be detected in plasma.

Sensitization of nociceptors by prostaglandin E2-glycerol contributes to hyperalgesia in mice with sickle cell disease.

The ability of R-flurbiprofen to block the synthesis of PGE2-G and to normalize levels of 2-AG suggests that R-Flurbip rofen may be beneficial to treat pain in SCD, thereby reducing the use of opioids to relieve pain.
...

References

SHOWING 1-10 OF 60 REFERENCES

Inhibition of Noxious Stimulus‐Induced Spinal Prostaglandin E2 Release by Flurbiprofen Enantiomers

The data suggest that antinociception produced by R‐flurbiprofen is mediated at least in part by inhibition of stimulated spinal P GE2 release and support the current view that increased spinal PGE2 release significantly contributes to nociceptive processing.

Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors

It is concluded that the contribution of CB1-type receptors expressed on the peripheral terminals of nociceptors to cannabinoid-induced analgesia is paramount, which should enable the development of peripherally acting CB1 analgesic agonists without any central side effects.

R-flurbiprofen: isomeric ballast or active entity of the racemic compound?

Using the pure enantiomers of flurbiprofen it appears possible to establish a more specific drug treatment: the R-enantiomer in occasional pain, the S-encenteromer in rheumatic disorders.

Crucial Role of CB2 Cannabinoid Receptor in the Regulation of Central Immune Responses during Neuropathic Pain

The enhanced manifestations of neuropathic pain were replicated in irradiated wild-type mice reconstituted with bone marrow cells from CB2 knock-outs, thus demonstrating the implication of the CB2 receptor expressed in hematopoietic cells in the development of neuropathy pain at the spinal cord.

Molecular architecture of endocannabinoid signaling at nociceptive synapses mediating analgesia

The striking positioning of the molecular players of 2‐ AG synthesis and action at nociceptive excitatory synapses suggests that pharmacological manipulation of spinal 2‐AG levels may be an efficacious way to regulate pain sensation.

Inhibition of NF-kappaB and AP-1 activation by R- and S-flurbiprofen.

It is shown that R-flurbiprofen has additional anti-inflammatory activity comparable with that of dexamethasone in the zymosan-induced paw inflammation model in rats, and might be a useful drug in inflammatory or other diseases in which increased or constitutive NF-kB and AP-1 activation are involved in the pathophysiological processes.

Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity.

It is shown that CB(2) cannabinoid receptor expression increases in striatal microglia of Huntington's disease transgenic mouse models and patients, support a pivotal role for CB( 2) receptors in attenuating microglial activation and preventing neurodegeneration that may pave the way to new therapeutic strategies for neuroprotection in Huntington’s disease as well as in other Neurodegenerative disorders with a significant excitotoxic component.

Effects of flurbiprofen enantiomers on pain-related chemo-somatosensory evoked potentials in human subjects.

The present data indicate that both enantiomers of flurbiprofen produce analgesic effects and a reduction of the quantitatively most important side effects in the gastrointestinal tract might be achieved by employing (R)-flurbiprfen in pain therapy.

Intrathecal minocycline attenuates peripheral inflammation‐induced hyperalgesia by inhibiting p38 MAPK in spinal microglia

Findings show that minocycline given IT produces a potent and consistent antinociception in models of tissue injury and inflammation‐evoked pain, and they provide strong support for the idea that this effect is mediated by direct inhibition of spinal microglia and subsequent activation of p38 in these cells.

Cyclooxygenase‐independent actions of cyclooxygenase inhibitors

Differences in cyclooxygenase‐independent mechanisms may have consequences for the specific use of these drugs in individual patients because additional effects may either enhance the efficacy or reduce the toxicity of the respective compounds.
...